Fundraising FoxPerceptive Xontogeny Venture
Venture capitalNew York · 1 people tracked
Find your way into Perceptive Xontogeny Venture
Sign up to see every warm intro you have to Perceptive Xontogeny Venture
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Perceptive Xontogeny Venture team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Fund manager profile
Perceptive Xontogeny Venture is a venture fund manager based in New York. SEC filings show 4 venture funds on record, most recently Perceptive Xontogeny Venture Fund II, LP ($515M offering) filed May 2021.
Source: SEC EDGAR Form D filings. Firm website data not yet available.
Team · 1 people
from public directories
What they invest in
from 12 of 13 portfolio companiesBiotech ×9Healthtech ×7Medical Devices ×3AI & Machine Learning ×2Digital Health ×2Cleantech ×1Climate Tech ×1EdTech ×1
HQs:United States×8
Investments · 13 tracked
founders shown can be your intro pathBy year:2025 · 32024 · 12023 · 12022 · 12021 · 17 dated
Apogee Therapeutics develops engineered antibody therapies to treat inflammatory and immune diseases with reduced injection frequency compared to existing treatments.
BiotechHealthtechMedical Devices
Michael Henderson(Chief Executive Officer and Director)in
Co-investorsAccess BiotechnologyRA CapitalWellington ManagementBlackstone Life SciencesRTW Investments L.P.Venrock Healthcare Capital Partners
Avalyn Pharma develops inhaled therapies for pulmonary fibrosis, using a nebulization approach that delivers treatment directly to the lungs to reduce the tolerability problems of existing oral therapies.
BiotechHealthtech
Lyn Baranowski(CEO)in
Co-investorsAndera PartnersCatalio Capital Management, LPF-Prime CapitalInVivium CapitalNorwest Venture PartnersPivotal Life Sciences+9 more
Biopharmaceutical company using computational biology to identify and develop novel peptide therapies, including AXT107 for retinal/eye diseases.
BiotechBethesda, US
Aleksander S. Popel, PhD(Executive Officer, Director)Jordan J. Green(Executive Officer, Director)inWendy Perrow(Executive Officer, Director)in
Co-investorsRapha Capital Management, LLC
Biotechnology company developing the LOCOcyte cell-therapy platform for local dosing of immunotherapeutics.
Co-investorsLongitude CapitalPappas CapitalRock Springs Capital
Launched by Samsara in partnership with CAR T pioneers, advancing a clinically validated CD22 CAR T for lymphoma.
BiotechSan Mateo, US
Gina Chapman(Executive Officer, Director)inAnup Radhakrishnan(Executive Officer)inCassandra Gianna Luca(Director)Jeffrey Walsh(Director)Krishnan Viswanadhan(Director)
BoardAbraham Bassan(Director)
Co-investorsNextech InvestRed Tree VentureSamsara BioCapitalWellington ManagementAlly Bridge GroupJanus Henderson Investors+1 more
Delve develops molecular next-generation sequencing (mNGS) tests that diagnose infections in cerebrospinal fluid and other clinical samples, enabling rapid pathogen identification for patients with difficult-to-diagnose infections.
AI & Machine LearningBiotechDigital HealthHealthtechMedical Devices
Dr. Joseph DeRisi(Founder)
Co-investorsGV (Google Ventures)Section 32
Galvanize provides customized technical education and training programs to help enterprise teams build skills in AI, machine learning, XP and Agile practices, data pipelines, and cloud operations.
AI & Machine LearningEdTechEnterprise SoftwareFuture of WorkDenver, US
Christopher C. Onan(Executive Officer)James Deters(President and Chief Executive Officer)Lawrence Mandes(Managing Director, New Markets)in
BoardDaniel Pianko(Director)Tatiana Goldstein(Director)Jerrold Miller(Director)
Co-investorsSofinnova PartnersTeamworthy VenturesThe Colorado Impact FundVTF CapitalAlly Bridge GroupCatalyst Investors+5 more
Galvanize Climate Solutions is an investment firm focused on the energy transition, deploying capital across areas such as climate risk analytics and clean energy.
CleantechClimate TechEnergy
Veery Maxwell(Founder)in
Co-investorsABS Capital PartnersBlue Haven InitiativeGalvanize Climate SolutionsAlly Bridge GroupFidelity InvestmentsGilmartin Capital LLC+4 more
Galvanize Therapeutics develops surgical ablation technology using its proprietary Aliya Pulsed Electric Field (PEF) energy to destroy soft tissue cells through regulated cell death mechanisms.
BiotechHealthtechMedical DevicesRedwood City, US
Doug Godshall(Executive Officer, Director)inSteve Anheier(Executive Officer)in
BoardJonathan Waldstreicher(Executive Officer)Antoine Papiernik(Director)inSeth Harrison(Director)Zack Scott(Director)in
Co-investorsNorwest Venture PartnersAlly Bridge GroupATPFidelity InvestmentsGilmartin Capital LLCJanus Henderson Investors+2 more
HealthtechSan Diego, US
Jim Chauvapun(Executive Officer, Director)Dirk van den Boom(Executive Officer, Director)
BoardFrederick Callori(Director)Chris Garabedian(Director)
Tellus Therapeutics is a biopharmaceutical company developing therapeutics.
BiotechDigital HealthHealthtechHillsborough, US
Eric Benner, M.D., Ph.D.(Acting CSO and Co-founder)Jason Kralic, Ph.D.(CEO and Co-founder)Simon Gregory, Ph.D.(Scientific Co-Founder and Scientific Advisory Board Member)Jason E. Karlic(Executive Officer, Director)Alex M. Ruckdaeschel(Director)Eric J. Benner(Executive Officer, Director)
Co-investorsMedblue
TORL BioTherapeutics develops antibody-drug conjugates (ADCs) targeting Claudin 6 (CLDN6) for the treatment of solid tumors such as ovarian, lung, endometrial, and testicular cancers.
BiotechHealthtechCulver City, US
Dave LicatainAran Maree M.D.inMark Alles(Executive Officer, Director)Mark Attanasio(Director)David Licata(Executive Officer, Director)Neil O'Brien(Director)
Co-investorsOCV PartnersRA CapitalCowen Healthcare InvestmentsGoldman SachsVertex Ventures HC
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Exits · 3
2 IPOs · 1 acquisitions · showing 2Apogee TherapeuticsNASDAQ: APGEAvalyn Pharma IncNASDAQ: AVLN
Portfolio news
latest coverage across their companiesIPO stake values · per SEC filings · 2
Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.
| Company | Owned | IPO price | At IPO | Stake value |
|---|---|---|---|---|
| Apogee Therapeutics | 3.4% | $62.00 | Mar 2024 | $122.6M |
| Avalyn Pharma Inc | 5.4% | $18.00 | Apr 2026 | $40.5M |
Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).
Frequently asked questions
- How many investments has Perceptive Xontogeny Venture made?
- Perceptive Xontogeny Venture has 13 tracked investments, 3 of which have exited, including 3 dated in the last 24 months.
- Where is Perceptive Xontogeny Venture located?
- Perceptive Xontogeny Venture is headquartered in New York, US.